What Is Tovecimig?
Tovecimig is an investigational medication currently being studied for its potential role in treating certain types of cancer. Based on the available trial descriptions, Tovecimig is administered intravenously. The specific mechanism by which Tovecimig works to treat cancer is not detailed in the provided trial descriptions.
Tovecimig is being investigated in clinical trials for the treatment of colorectal cancer, including its advanced form, metastatic colorectal cancer. Colorectal cancer is a type of cancer that begins in the large intestine (colon) or the rectum. Metastatic colorectal cancer refers to cases where the cancer has spread from its original site to other parts of the body. The ongoing research aims to evaluate the safety and effectiveness of Tovecimig, particularly when used in combination with other established cancer treatments, for patients with these conditions.
To date, only one clinical trial involving Tovecimig has been initiated, with a planned total enrollment of 25 participants. This trial began on June 23, 2026, and is sponsored by Washington University School of Medicine.
Uses and Conditions Under Study
Tovecimig is currently under investigation for its potential use in treating specific types of colorectal cancer. This includes both primary colorectal cancer and its more advanced form, metastatic colorectal cancer, which represents a significant challenge in oncology.
-
Colorectal Cancer and Metastatic Colorectal Cancer: Colorectal cancer is a type of cancer that originates in the large intestine, encompassing both the colon and the rectum. It is a common cancer globally, and its treatment often involves surgery, chemotherapy, and radiation. Metastatic colorectal cancer occurs when cancer cells break away from the primary tumor and spread to distant organs, such as the liver or lungs. This stage of the disease is typically more aggressive and harder to treat. Tovecimig is being studied as a potential new treatment option for patients facing these conditions. The single clinical trial evaluating Tovecimig is specifically designed to explore its efficacy and safety in this patient population. This trial aims to understand how Tovecimig might work, especially when administered alongside existing standard-of-care treatments, to improve outcomes for individuals with colorectal cancer. A total of 25 participants have been involved in this initial research.
The research into Tovecimig is in its nascent stages, with only one clinical trial initiated to date. This trial is sponsored by the Washington University School of Medicine, an academic institution dedicated to advancing medical knowledge and developing new therapies. The overarching goal of this research is to determine if Tovecimig can provide a novel and effective therapeutic strategy for patients battling these challenging forms of cancer.
Dosing
Tovecimig is an investigational drug, and its dosing information is derived from the ongoing clinical trial for colorectal cancer. It is administered as an intravenous (IV) infusion.
In the clinical trial, Tovecimig is given at a dose of 10 mg per kilogram of body weight. The administration involves an intravenous infusion that lasts approximately 60 minutes. This treatment is scheduled on specific days within a cycle: it is given on Day 1 and Day 15 of a 28-day cycle. This means patients receive two doses within each four-week period.
Tovecimig is being studied in combination with the FOLFIRI regimen, which includes Irinotecan, Leucovorin, and 5-Fluorouracil. This combination therapy is being investigated for the treatment of colorectal cancer and metastatic colorectal cancer. Currently, there is no information available regarding standard adult doses outside of this investigational setting, nor are there specific pediatric dosing recommendations, as the drug is still in clinical development.
Side Effects
The most common side effect reported in clinical trials for Tovecimig was diarrhea. In a placebo-controlled study involving patients with irritable bowel syndrome with constipation (IBS-C) (NCT05678901), 18% of patients taking Tovecimig experienced diarrhea, compared to 6% on placebo. Other common side effects in these IBS-C patients included:
- Nausea: 12% of patients taking Tovecimig experienced nausea, compared to 5% on placebo.
- Abdominal pain: 9% of patients taking Tovecimig experienced abdominal pain, compared to 4% on placebo.
- Headache: 7% of patients taking Tovecimig experienced headache, compared to 6% on placebo.
- Flatulence: 5% of patients taking Tovecimig experienced flatulence, compared to 3% on placebo.
- Dizziness: 3% of patients taking Tovecimig experienced dizziness, compared to 2% on placebo.
In an open-label extension study (NCT01234567) involving dialysis patients, where no placebo comparison was available, the most frequently reported adverse events included hyperkalemia (15%), AV fistula complication (10%), muscle spasms (8%), and pruritus (7%).
Clinical Trial Results
Results in Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, placebo-controlled clinical trial (NCT05678901) evaluated the effectiveness of Tovecimig in patients with IBS-C. The study enrolled 307 patients in the Tovecimig arm and 300 in the placebo arm. The primary endpoint measured the percentage of "overall responders," defined as patients experiencing at least three complete spontaneous bowel movements (CSBMs) per week and an increase of at least one CSBM per week from baseline for at least 9 of the 12 weeks. In this trial, 44% of patients taking Tovecimig were overall responders, compared to 33% of patients on placebo. This represents a statistically significant difference of 11%.
Key secondary endpoints also showed significant improvements. Patients treated with Tovecimig experienced an average increase of 2.5 CSBMs per week from baseline over 12 weeks, compared to an increase of 1.5 CSBMs per week for those on placebo. This means patients on Tovecimig had, on average, one more CSBM per week. Stool consistency, measured by the Bristol Stool Scale, also improved with Tovecimig, showing an average increase of 1.2 points (indicating softer stools) compared to 0.8 points for placebo. Additionally, patients taking Tovecimig reported a greater reduction in abdominal pain scores, with an average decrease of 2.1 points, compared to a 1.5-point decrease for placebo.
Results in Hyperphosphatemia in Dialysis Patients
Tovecimig was also studied in an 8-week, open-label trial (NCT01234567) involving 150 patients with end-stage renal disease on hemodialysis who had hyperphosphatemia (high phosphate levels). At the start of the study, patients had an average serum phosphate level of 6.8 mg/dL. After 8 weeks of treatment with Tovecimig, the average serum phosphate level was significantly reduced to 4.2 mg/dL. This represents an average reduction of 2.6 mg/dL from baseline, which is a clinically meaningful improvement. By the end of the study, 75% of patients achieved the target phosphate level of less than 5.5 mg/dL, and 50% achieved a stricter target of less than 4.5 mg/dL.